View clinical trials related to Cancer.
Filter by:The purpose of this study was to assess the 90-day safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain in subjects on around-the-clock opioids for their persistent cancer pain.
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain. The study medication is administered under the tongue as a simple spray and can be self-administered by patients or assisted by their caregivers. Patients are titrated to an effective-dose of fentanyl sublingual spray in the open-label titration period and then proceed to the double-blind randomized period where they randomly receive 7 treatments with fentanyl sublingual spray and 3 treatments with placebo. Patients are treated for up to a total of 6-7 weeks (including both the open-label titration and the double-blind randomized periods).
The purpose of this study is to determine if CNTO 888 is safe and to determine how long CNTO 888 stays in the body and what effects it might have on cancer tumors.
The purpose of this study is to determine the safety and pharmacokinetics of TAK-285 in patients with advanced cancer.
The occurrence of acute respiratory failure (ARF) is often seen by oncologists as a terminal phase of the disease, this view being based on studies reporting limited survival at considerable costs in such patients. A large proportion of cancer patients with severe respiratory failure are denied admission to an ICU because intensive care specialists are aware that intubation and mechanical ventilation are both strong predictors of mortality in critically ill cancer patients. This holds particularly true in the subset of patients who are not receiving chemotherapy or radiotherapy because of the advanced stage of their disease, and who are also not affected by an episode of ARF, related to a reversible cause. These patients often receive oxygen therapy and morphine in an attempt to improve oxygenation and/or relieve the ensuing dyspnea. Non-invasive mechanical ventilation (NIV) is now the first line treatment of ARF in selected populations (e.g., those with COPD) and has been used sporadically as a potential treatment of acute respiratory failure in patients with a "do-not-intubate" order. The International Consensus Conference on Intensive Care Medicine stated that "the use of NIV may be justified in selected patients who are "not to be intubated" and may provide patient comfort and facilitate physician-patient interaction." "Early" NIV has been successfully used so far in cancer patients only to prevent intubation among those with hematologic malignancies, while a pilot study has assessed the feasibility of NIV also as a "palliative" treatment of end-stage solid cancer patients. So far we are lacking data about the "pure palliative" effects of NIV,in patients with end-stage solid cancer. The aim of this multicenter randomised study will be to evaluate on a large scale the feasibility, clinical efficacy and impact on quality of life and dyspnea of NIV versus standard medical in patients with respiratory failure, not related to a reversible cause, and solid cancer needing palliative care treatment.
The purpose of this study is to determine the effective dose range and to demonstrate a non-effective dose range of Sativex in patients with advanced cancer, who experience inadequate pain relief even though they are on optimized chronic opioid therapy.
The purpose of this study is to test the safety of PRLX 93936 and see what kind of effect it has on patients and their cancer. This study will also determine the highest dose of PRLX 93936 that can be given without causing adverse side effects and the dose of PRLX 93936 that should be used in future studies.
The purpose of this study was to compare the effectiveness of epoetin alfa treatment on hemoglobin (Hb) response, quality of life (QoL), health care resource utilization and patient productivity when epoetin alfa was administered during chemotherapy to patients with mild anemia or after waiting until patients became moderately anemic. Patients with lymphoma, chronic lymphocytic leukemia (CLL) or Multiple Myeloma (MM) were studied.
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of rIL-21 and Caelyx in cancer patients who have relapsed after, or have persistent disease after, first line therapy. Patients will be treated for 6 months.
This protocol is a sub-study of the ongoing "Protect Health and Reduce Cancer Risk" study conducted in Shanghai, China, and sponsored by the Shanghai Cancer Institute, Vanderbilt University, and the National Cancer Institute. The parent study is designed to examine the relationship of diet, lifestyle, occupational, and environmental risk factors, as well as genetic variation, to cancer incidence in a large cohort of men in women between 40 and 70 years of age. The current sub-study will assess the validity and reliability of a new physical activity questionnaire for use in the parent study and to evaluate whether different types of activity and the frequency, intensity, and duration of activity are associated with markers that have been linked to cancer risk, such as C-reactive protein, interleukin 6 and soluble tumor necrosis factor alpha. Participants in the current 12-month study are selected from among men and women participating in the "Protect Health and Reduce Cancer Risk" study. Participants keep a diary of their physical activity and complete two 30-minute interviews about their physical activity, one at the beginning and one at the end of the study period. Every 3 months for 7 consecutive days, they wear a pager-sized activity monitor on their waist that records their physical activity patterns during that period of time. They provide blood and urine samples four times during the study and, at the end of the study, undergo a health examination that includes an electrocardiogram, body composition measurement, and physical fitness test. The fitness test is a step-test consisting of 3-minute stages in which the subject successively increases the stepping speed until reaching 85 percent of his or her predicted maximal heart rate. Blood and urine samples are analyzed for levels of nutrients and certain proteins, and are stored for future studies related to nutrition and physical activity and possibly for genetic studies related to health, nutrition, exercise, or disease.